SG11201907315PA - Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient - Google Patents
Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredientInfo
- Publication number
- SG11201907315PA SG11201907315PA SG11201907315PA SG11201907315PA SG11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA SG 11201907315P A SG11201907315P A SG 11201907315PA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- myopia
- international
- agent
- osaka
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Prostheses (AREA)
- Undergarments, Swaddling Clothes, Handkerchiefs Or Underwear Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WI P0 I P C T omit olo 010TH olo 0111 X10111111 lII ow (10) International Publication Number WO 2018/174149 Al (51) International Patent Classification: A61K 31/439 (2006.01) A61P 27/10 (2006.01) (21) International Application Number: PCT/JP2018/011361 (22) International Filing Date: 22 March 2018 (22.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201702378S 23 March 2017 (23.03.2017) SG (71) Applicants: SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer Block C, Singapore, 168753 (SG). SANTEN PHARMA- CEUTICAL CO., LTD. [JP/JP]; 9-19, Shimoshinjo 3- chome, Higashiyodogawa-ku, Osaka-shi, Osaka, 5338651 (JP). (72) Inventors: TAN, Donald; c/o Singapore Eye Research In- stitute, 11 Third Hospital Ave, Singapore, 168751 (SG). BEUERMAN, Roger; c/o Singapore Eye Research In- stitute, 11 Third Hospital Ave, Singapore, 168751 (SG). SAW, Seang-Mei; c/o Singapore Eye Research Institute, 11 Third Hospital Ave, Singapore, 168751 (SG). UPAD- HYAY, Aradhana; 283, Bedok South Avenue 3, unit 14-43, Singapore, 465460 (SG). KATO, Masatomo; c/ o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP). INABA, Takaaki; c/o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP). (74) Agent: SAMEJIMA, Mutsumi et al.; AOYAMA & PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, Kakuda-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) N 1-1 O \" (57) : The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, 0 comprising tiotropium as an active ingredient. (54) Title: AGENT FOR PREVENTING MYOPIA, TREATING MYOPIA, AND/OR PREVENTING MYOPIA PROGRESSION COMPRISING TIOTROPIUM AS ACTIVE INGREDIENT
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201702378S | 2017-03-23 | ||
PCT/JP2018/011361 WO2018174149A1 (en) | 2017-03-23 | 2018-03-22 | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907315PA true SG11201907315PA (en) | 2019-09-27 |
Family
ID=63586549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907315PA SG11201907315PA (en) | 2017-03-23 | 2018-03-22 | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
Country Status (11)
Country | Link |
---|---|
US (1) | US11642350B2 (en) |
EP (1) | EP3600306A4 (en) |
JP (1) | JP7016880B2 (en) |
KR (1) | KR102633606B1 (en) |
CN (1) | CN110505876A (en) |
CA (1) | CA3055891A1 (en) |
EA (1) | EA201992234A1 (en) |
PH (1) | PH12019502145A1 (en) |
SG (1) | SG11201907315PA (en) |
TW (1) | TWI816660B (en) |
WO (1) | WO2018174149A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020251926A1 (en) * | 2019-06-10 | 2020-12-17 | Jenivision Inc. | Methods and formulations for treating vision disorders |
CN116785286A (en) * | 2020-10-10 | 2023-09-22 | 远大生命科学(武汉)有限公司 | Use of penehyclidine in the treatment or prevention of vision-damaging ocular disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2200468A1 (en) * | 1994-10-27 | 1996-05-09 | Wayne J. Thompson | Muscarine antagonists |
KR100488644B1 (en) | 2000-10-12 | 2005-05-11 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | Novel tiotropium-containing inhalation powder |
US6908928B2 (en) * | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
SG151148A1 (en) | 2007-10-05 | 2009-04-30 | Singapore Health Services Pte | Method and/or kit for determining response to muscarinic receptor antagonist treatment |
WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
US20160009705A1 (en) * | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
CN107920984A (en) | 2015-06-18 | 2018-04-17 | 远视眼治疗有限责任公司 | The composition of stable storing and the not positive method for the treatment of ophthalmic refractive |
JP7095873B2 (en) * | 2016-04-11 | 2022-07-05 | ユニバーシティ・オブ・キャンベラ | Ophthalmic composition comprising levodopa, antioxidant and aqueous carrier |
-
2018
- 2018-03-22 WO PCT/JP2018/011361 patent/WO2018174149A1/en unknown
- 2018-03-22 KR KR1020197030849A patent/KR102633606B1/en active IP Right Grant
- 2018-03-22 JP JP2019549489A patent/JP7016880B2/en active Active
- 2018-03-22 SG SG11201907315PA patent/SG11201907315PA/en unknown
- 2018-03-22 CA CA3055891A patent/CA3055891A1/en active Pending
- 2018-03-22 CN CN201880019458.8A patent/CN110505876A/en active Pending
- 2018-03-22 EP EP18772076.8A patent/EP3600306A4/en active Pending
- 2018-03-22 EA EA201992234A patent/EA201992234A1/en unknown
- 2018-03-22 US US16/495,350 patent/US11642350B2/en active Active
- 2018-03-22 TW TW107109771A patent/TWI816660B/en active
-
2019
- 2019-09-19 PH PH12019502145A patent/PH12019502145A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102633606B1 (en) | 2024-02-02 |
PH12019502145A1 (en) | 2020-06-15 |
WO2018174149A1 (en) | 2018-09-27 |
EA201992234A1 (en) | 2020-02-05 |
JP2020514347A (en) | 2020-05-21 |
CA3055891A1 (en) | 2018-09-27 |
JP7016880B2 (en) | 2022-02-07 |
EP3600306A4 (en) | 2020-12-02 |
EP3600306A1 (en) | 2020-02-05 |
CN110505876A (en) | 2019-11-26 |
TWI816660B (en) | 2023-10-01 |
KR20190127885A (en) | 2019-11-13 |
US20200147098A1 (en) | 2020-05-14 |
TW201840313A (en) | 2018-11-16 |
US11642350B2 (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809822SA (en) | Atropine-containing aqueous composition | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201907034PA (en) | Methods of treating influenza | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201804405PA (en) | Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration | |
SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
SG11201810801QA (en) | Brain delivery protein | |
SG11201908052PA (en) | Lipid-based nanoparticles with enhanced stability | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia |